Keywords
Cannabis
Cannabidiol
Motor disorders
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To understand the effectiveness of medicinal Cannabis use in treating the motor and non-motor symptoms characteristic of Parkinson's Disease (PD). Bibliographic review: Treatment with Cannabis, specifically Cannabidiol (CBD), has been studied for various neurodegenerative diseases, including PD. While CBD shows potential in alleviating symptoms such as dystonia and dyskinesias, its efficacy in the motor symptoms of PD still lacks robust evidence. Cannabinoid receptors CB1 and CB2 are present in crucial areas for motor coordination, and CBD may influence dopaminergic neurotransmission, but the results regarding its effect on PD motor symptoms are inconsistent. Additionally, although CBD may improve non-motor symptoms such as anxiety and sleep disorders, adverse effects including sedation and hallucinations are concerning. Final considerations: The use of cannabis derivatives has not shown significant advantages in Parkinson's Disease. Cannabidiol has been shown to be insufficient in treating motor symptoms, and its uncertain adverse effects make its use risky.
References
ALBIN RL, et al. The functional anatomy of basal ganglia disorders. Trends In Neurosciences, 1989; 12: 366-375.
ARAÚJO M, et al. Mecanismo de ação dos canabinoides: visão geral. Brazilian Journal Of Pain, 2023; 6: 109-13.
ARMSTRONG MJ e OKUN MS. Diagnosis and Treatment of Parkinson Disease. Jama, 2020; 323(6): 548.
BATISTA J, et al. Efeitos adversos do uso dos canabinoides: qual o paradigma de segurança? Brazilian Journal Of Pain, 2023; 6: 38-43.
CABREIRA V e MASSANO, J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Médica Portuguesa, 2019; 32: 661.
CAMARGO MF, et al. Canabinoides como uma nova opção terapêutica nas doenças de Parkinson e de Alzheimer: uma revisão de literatura. Revista brasileira neurologia, 2019; 55(2): 17-32.
CASSANO T, et al. From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Frontiers in pharmacology, 2020; 11: 124.
CHEN Z, et al. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiology Of Disease, 2020; 134: 104700.
CHURCH FC. Treatment options for motor and non-motor symptoms of Parkinson’s disease. Biomolecules, 2021; 11(4): 612.
COORAY R, et al. Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review. Molecular Neurobiology, 2020; 57: 4878–4890.
CRAVANAS B, et al. The effects of Cannabis on hallucinations in Parkinson's disease patients, Journal of the Neurological Sciences, 2020; 15 (419): 117206.
CRIPPA JAS et al; Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? European Archives of Psychiatry and Clinical Neuroscience, 2019; 269(1): 121-133.
DEUEL LM e SEEBERGER LC. Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis. Neurotherapeutics, 2020; 17(4): 1434-1455.
FARIA SM, et al. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease. Journal Of Psychopharmacology, 2020; 34(2): 189-196.
FIGURA M, et al. Cannabis in Parkinson’s Disease - the patient’s perspective versus clinical trials: a systematic literature review. Neurologia i Neurochirurgia Polska, 2022; 56: 21–27.
HAYES MT. Parkinson's Disease and Parkinsonism. The American Journal Of Medicine, 2019; 132: 802-807.
JUNIOR NCF, et al. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson’s Disease and l-DOPA-Induced Dyskinesia. Neurotoxicity Research, 2019; 37: 12–29.
KANJANARANGSICHAI A, et al. Cannabidiol-enriched cannabis extraction product in Parkinson's disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital. J Neurosci Rural Pract, 2022; 13(4): 663-668.
KLUGER BM, et al. Cannabinoids in movement disorders. Parkinsonism & Related Disorders, 2022; 102: 124-130.
LACROIX C, et al. What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps? Frontiers in pharmacology, 2022; 13: 883987.
LANCIEGO JL, et al. Functional Neuroanatomy of the Basal Ganglia. Cold Spring Harbor Perspectives In Medicine, 2012; 2: 9621.
PAES-COLLI Y, et al. Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice. Frontiers in Cellular Neuroscience, 2022; 16: 917164.
PATRICIO F, et al. Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson’s disease. Frontiers in Pharmacology, 2020; 11: 595635.
RYMAN SG e POSTON KL. Biomarcadores de ressonância magnética de sintomas motores e não motores na doença de Parkinson. Parkinsonismo e distúrbios relacionados, 2020; 73: 85-93.
SANTOS GF, et al. Doença de Parkinson: Padrão epidemiológico de internações no Brasil. Research, Society and Development, 2022; 11: 13511124535.
SIMON DK, et al. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics In Geriatric Medicine, 2020; 36: 1-12.
TAMBE SM, et al. Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications. Journal of Integrative Medicine, 2023; 21(3): 236-244.
THALER A e ALCALAY RN. Diagnosis and Medical Management of Parkinson Disease. Continuum: Lifelong Learning in Neurology, 2022; 28(5): 1281-1300.